Pyrrolidine

Pyrrolidine

SCHEMBL6930404

C1CCNC1.NC(=S)S.S.S

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
CXCR4 P61073 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
NOS2 P35228 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrrolidine SCHEMBL157612 0.97
Pyrrolidine SCHEMBL27968527 0.94 ALDH1A1 (0.44) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Piperidine SCHEMBL476425 0.94 ALDH1A1 (0.53) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Piperidine SCHEMBL27755341 0.94 ALDH1A1 (0.53) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Pyrrolidine SCHEMBL14815975 0.94 ALDH1A1 (0.44) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Piperidine SCHEMBL1396086 0.94 ALDH1A1 (0.53) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Pyrrolidine SCHEMBL14815556 0.94 ALDH1A1 (0.44) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Pyrrolidine SCHEMBL1478729 0.94 ALDH1A1 (0.44) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Piperidine SCHEMBL27925102 0.94 ALDH1A1 (0.53) ALDH1A1CXCR4SMN1; SMN2HSD17B10KDM4E
Piperidine SCHEMBL27977836 0.92 ALDH1A1 (0.50) ALDH1A1CXCR4SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030181495-A1 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor MEDINOX, INC. 2003-09-25 US disclosed
US-6596770-B2 Disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of)the species that induce the expression of nitric oxide synthase MEDINOX, INC. 2003-07-22 US disclosed
EP-1089723-A4 THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR MEDINOX INC (US) 2003-07-16 EP disclosed
US-6589991-B1 Treating diseases associated with nuclear factor kappa B pathway; nitric oxide synthase inhibitors, antiinflammatory agents MEDINOX, INC. 2003-07-08 US disclosed
US-20020151540-A1 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor MEDINOX, INC. 2002-10-17 US disclosed
US-6316502-B1 ADMINISTERING DISULFIDE DERIVATIVE OF DITHIOCARBAMATE COMPOUND TO BIND TO IRON MEDINOX, INC. 2001-11-13 US disclosed
CN-1315856-A Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor MEDINOX INC (US) 2001-10-03 CN disclosed
US-6274627-B1 ADMINISTERING COMPOUNDS SUCH AS N-METHYL-D-GLUCAMINE DITHIO-CARBAMATE DISULFIDE FOR IN VIVO REDUCTION OF FREE RADICAL LEVELS IN A SUBJECT MEDINOX, INC. 2001-08-14 US disclosed
EP-1089723-A1 THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR Medinox, Inc. (US) 2001-04-11 EP disclosed
US-6093743-A FOR IN VIVO REDUCTION OF LEVELS OF NITRIC OXIDE, SUCH AS ARE INDUCED BY A VARIETY OF DISEASE STATES, AND FOR TREATMENT OF INFECTIOUS AND/OR INFLAMMATORY CONDITIONS MEDINOX INC. (US) 2000-07-25 US disclosed
WO-1999066918-A9 THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR MEDINOX INC (US) 2000-03-30 WO disclosed
WO-1999066918-A1 THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR MEDINOX, INC. (US) 1999-12-29 WO disclosed